Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program
Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program
Aptevo Therapeutics宣布临床项目和一项临床前计划取得进展
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ALG.APV-527 clinical trialCohort 5 dosing imminent, trial more than 50% enrolled
APVO436 Phase 1b/2 dose optimization trial initiation expected 1H 2024Premier CRO, Prometrika, engaged as partner for dose optimization trial to evaluate APVO436 in frontline AML in combination with venetoclax + azacitidine in venetoclax naïve patients
APVO711 demonstrates its ability to induce tumor killing properties in preclinical studiesAPVO711 dual mechanism checkpoint inhibitor with unique precision targeting capabilities progressing towards IND
从进行性疾病诊断改善为持续稳定疾病诊断超过九个月的乳腺癌患者现已成功过渡到更高的剂量水平，从而有可能获得更大的临床益处 ALG.APV-527 临床试验第 5 组队列即将给药，超过 50% 的试验注册人数
APVO436 1b/2 阶段剂量优化试验预计于 2024 年上半年启动首席合同研究组织 Prometrika 作为剂量优化试验的合作伙伴，该试验旨在评估 Venetoclax 天真患者一线急性髓细胞白血病联合使用 venetoclax + azacitidine 后一线急性髓细胞白血病中的 APVO436
APVO711 显示其在临床前研究中诱发肿瘤杀灭特性的能力具有独特精确靶向能力的 APVO711 双机制检查点抑制剂正在向 IND 迈进
SEATTLE...
华...
登录免费看全文
登录/注册